Disease: invasive candidiasis

Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate

mycolabadmin

Doctors and researchers use standard definitions to determine if antifungal treatments work in clinical trials. This debate examines whether the standards created in 2008 are still appropriate today. Key concerns include whether stable disease should always count as treatment failure, how to handle deaths from other causes, and whether newer testing methods should be incorporated. The expert panel concluded these definitions need updating to reflect modern treatment options and patient needs.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

mycolabadmin

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »

Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics

mycolabadmin

This editorial discusses the growing challenge of fungal infections worldwide, which disproportionately affect people with weakened immune systems. New diagnostic tools using molecular testing can now quickly identify fungal infections, while researchers are developing novel treatments including repurposed drugs and immune-boosting therapies. The article emphasizes that coordinated efforts among doctors, scientists, and public health officials are essential to combat rising antifungal resistance and improve patient outcomes.

Read More »

Insights into the structure, function, and impact of Candida albicans UPC2 gene on azole resistance; a mini-review

mycolabadmin

Candida albicans is a common fungal infection that doctors treat with azole medications, but the fungus is increasingly developing resistance to these drugs. Scientists have discovered that a gene called UPC2 plays a key role in this resistance by controlling the production of enzymes that help the fungus survive azole treatment. Understanding how UPC2 works could help develop new strategies to overcome drug-resistant fungal infections.

Read More »

Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005–2025)

mycolabadmin

This comprehensive review examines candida fungal infections in conflict-affected areas of Latin America and the Caribbean, where wars, violence, and displacement create dangerous conditions that make infections more likely and harder to treat. In these regions, mortality from candida bloodstream infections reaches 65% or higher among displaced populations, compared to about 45-60% in regular hospitals. The main problems are lack of proper diagnostic equipment, limited access to effective antifungal medications, malnutrition, overcrowding in shelters, and the emergence of drug-resistant fungal strains.

Read More »

Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives

mycolabadmin

Invasive candidiasis is a dangerous fungal infection affecting critically ill hospital patients. Current testing methods like blood cultures are slow and unreliable, so doctors are developing faster tests using DNA detection and biomarkers. A combination of new diagnostic tools and prompt treatment with antifungal medications is essential to improve survival rates and reduce complications from this serious infection.

Read More »
Scroll to Top